Authorship contributions
Karan Seegobin: Have made substantial contributions to conception and design, acquisition of data, and drafting the manuscript.
Muhamad Alhaj Moustafa: Have made substantial contributions to acquisition of data and drafting the manuscript.
Deborah Fischer: Have made substantial contributions to conception and design, acquisition of data, and drafting the manuscript.
Katelyn Keller: Have made substantial contributions to conception and design, acquisition of data, and drafting the manuscript.
Jacquelyn Hastings: Have made substantial contributions to conception and design, acquisition of data, and drafting the manuscript.
Mohamed A. Kharfan-Dabaja: Have made substantial contributions to conception and design, and revising it critically for important intellectual content.
Ernesto Ayala: Have made substantial contributions to conception and design, and revising it critically for important intellectual content.
Han W Tun: Have made substantial contributions to conception and design, and revising it critically for important intellectual content.
Liuyan Jiang: Have made substantial contributions to conception and design, and revising it critically for important intellectual content.
Conflict of interest
Mohamed A. Kharfan-Dabaja: reports consultancy for Pharmacyclics and Daiichi Sankyo
All other authors have no conflict of interest to declare
References
  1. Grisariu S, Avni B, Batchelor TT, et al. Neurolymphomatosis: International Primary CNS Lymphoma Collaborative Group report. International Primary CNS Lymphoma Collaborative Group Report. Blood. 2010; 115:5005-11.
  2. Baehring JM, Damek D, Martin EC, et al. Neurolymphomatosis. Neuro Oncol. 2003; 5:104-115.
  3. Novo M, Nowakowski GS, Micallef IN, et al. Clinical features, treatment and outcome of neurolymphomatosis: single institution experience. Hematological Oncology 2019. https://doi.org/10.1002/hon.80_2630
  4. Levin N, Soffer D, Grissaru S, et al. Primary T-cell CNS lymphoma presenting with leptomeningeal spread and neurolymphomatosis. J Neurooncol. 2008; 90:77-83.
  5. Wang CX, Wang H, Li J, et al. Brain metastasis of ALK positive anaplastic large cell lymphoma after a long-term disease-free survival in an old adult. Int J Clin Exp Pathol . 2014; 7:1182–1187.
  6. Chihara D, Fanale MA, Miranda RN, et al. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.PLoS One . 2018; 13: e0191461.
  7. Kuntegowdenahalli LC, Jacob LA, Komaranchath AS, Amirtham U. A rare case of primary anaplastic large cell lymphoma of the central nervous system. J Cancer Res Ther. 2015; 11:943-5.
  8. Gurion R, Mehta N, Migliacci JC, et al. Central nervous system involvement in T-cell lymphoma: A single center experience. Acta Oncol . 2016; 55:561–566.
  9. Shenkier TN, Blay JY, O’Neill BP, et al. Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group. J Clin Oncol 2005;23:2233-2239
Figure1. MRI brain axial and sagittal sections show bilateral nodular leptomeningeal enhancements in the posterior fossa and enhancement around both optic nerves (Before treatment). MRI after 2 cycles show no radiological evidence of residual lymphoma (After treatment).